Edwards Lifesciences CORP

Edwards Lifesciences reported strong second quarter 2026 results, exceeding sales growth expectations and raising full-year guidance for key product lines.

Edwards Lifesciences stockholders approved the amendment of the Long-Term Stock Incentive Compensation Program and re-elected all director nominees at the 2026 Annual Meeting.

Edwards Lifesciences announces Theodora Mistras as new CFO, succeeding Scott Ullem, effective May 29, 2026.

Edwards Lifesciences announced robust first-quarter 2026 financial results, exceeding expectations and leading to an upward revision of full-year sales and earnings guidance.

Edwards Lifesciences delivered robust fourth-quarter 2025 results, driven by strong TAVR and TMTT sales, and increased its full-year 2026 financial guidance.

Edwards Lifesciences announced the U.S. District Court blocked its acquisition of JenaValve Technology, leading to a revised, higher full-year 2026 adjusted EPS guidance.

Edwards Lifesciences reports increased Q3 sales driven by TAVR and TMTT products, but diluted EPS declined due to higher expenses, impairment charges, and significant litigation and tax disputes.

Edwards Lifesciences reported robust sales growth in its core structural heart therapies for Q2 2025, though net income declined due to discontinued operations and increased tax provisions, alongside new legal and regulatory challenges.

Edwards Lifesciences' Q1 2025 net sales increased by 6.2% year-over-year, driven by strong performance in Transcatheter Mitral and Tricuspid Therapies (TMTT) and Transcatheter Aortic Valve Replacement (TAVR) product groups.

Edwards Lifesciences reported a significant increase in net income for the third quarter of 2024, driven by the sale of its Critical Care business and strong performance in its TAVR and TMTT product lines.

Edwards Lifesciences reported a 7.9% increase in net sales for the first six months of 2024, driven by TAVR products, while also announcing the sale of its Critical Care product group and multiple acquisitions.

Edwards Lifesciences' first quarter 2024 results show a 9.5% increase in net sales, driven primarily by growth in transcatheter aortic valve replacement (TAVR) products.

Edwards Lifesciences reported a significant increase in net sales for 2025, driven by strong performance in its TAVR and TMTT product groups, despite a decrease in net income due to higher operational and litigation expenses.

Edwards Lifesciences' 2024 annual report highlights a strong financial year with increased net sales and strategic moves including the sale of its Critical Care product group and acquisitions to bolster its structural heart portfolio.

Edwards Lifesciences' 10-K filing details an employment agreement focusing on confidentiality and competition, alongside a review of the company's financial performance and strategic direction.

Wayne Markowitz, CVP, JAPAC of Edwards Lifesciences Corp, sold 146 shares of common stock on July 30, 2026 for $86.03 per share.

Wayne Markowitz, CVP, JAPAC of Edwards Lifesciences Corp, sold 9,628 shares of common stock on July 28, 2026 for $85.06 per share.

Bernard J Zovighian, CEO and a Director of Edwards Lifesciences Corp, sold 2,921 shares of common stock on July 27, 2026 for $83.93 per share.

Annette Bruls, CVP, EMEACLA of Edwards Lifesciences Corp, reported a transaction in 109 shares of common stock on July 11, 2026.

Edwards Lifesciences Corp. reports on equity grants and option awards to Chief Financial Officer Theodora Mistras.

Daniel J. Lippis of Edwards Lifesciences Corp. reported transactions involving common stock and employee stock options on July 10, 2026, executed under a Rule 10b5-1 trading plan.

Edwards Lifesciences issued a supplement to its proxy statement to clarify the treatment of abstentions and broker non-votes for the upcoming 2025 Annual Meeting of Stockholders.

Edwards Lifesciences' Spring 2025 stockholder presentation outlines the company's commitment to innovation, strategic growth drivers, and corporate governance.

Edwards Lifesciences Corporation will hold its annual meeting of stockholders on May 8, 2025, to vote on key proposals including the election of directors and executive compensation.

Edwards Lifesciences is asking stockholders to approve amendments to its employee stock purchase plans and highlights strategic steps taken to advance structural heart innovation.

Edwards Lifesciences emphasizes its focus on structural heart disease, innovation, and long-term shareholder returns in its Spring 2024 stockholder presentation.

Edwards Lifesciences Corporation will hold its annual meeting of stockholders on May 7, 2024, to vote on the election of directors, executive compensation, ratification of the accounting firm, and approval of the amended long-term stock incentive plan.

Vanguard Capital Management has filed a Schedule 13G reporting a 7.54% beneficial ownership stake in Edwards Lifesciences Corp.

The Vanguard Group filed an amendment to its Schedule 13G for Edwards Lifesciences Corp, reporting zero beneficial ownership following an internal realignment.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.5% of Edwards Lifesciences Corp's common stock.

Wellington Management Group LLP and its affiliates reported a 3.38% beneficial ownership stake in Edwards Lifesciences Corporation as of June 30, 2025.

The Vanguard Group has filed an amended Schedule 13G, reporting an 11.72% beneficial ownership stake in Edwards Lifesciences Corp as of December 31, 2024.